Lifetime QALE, cost, and cost-effectiveness estimates associated with Standard and Innovative TKA.
收藏NIAID Data Ecosystem2026-03-07 收录
数据链接：
官方服务：
资源简介：
*No obesity or comorbidity at baseline. †Baseline obesity, cardiovascular disease, and non-OA musculoskeletal disease. ‡ICER = incremental cost-effectiveness ratio in 2010 US$ per quality-adjusted life-year (QALY) gained, compared with standard TKA. “Cost saving” indicates greater QALYs achieved at a lower cost compared to standard TKA.
创建时间：
2013-05-06
